SCHEMBL5566331

SCHEMBL5566331

CN(C)Cc1n[c]c[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7618344 0.75 HRH4 (0.45)
SCHEMBL9946997 0.67
SCHEMBL405100 0.63 TAAR1 (0.48)
SCHEMBL590213 0.62
SCHEMBL7615355 0.61 CALM1 (0.37)
SCHEMBL7614190 0.61 HRH3 (0.31)
SCHEMBL18157883 0.61 CYP2D6 (0.35)
SCHEMBL16887768 0.61 CYP2D6 (0.32)
SCHEMBL7621930 0.60 HRH4 (0.43)
SCHEMBL7624142 0.60 CAPN1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140871-A4 THROMBIN OR FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2004-05-06 EP claimed
US-20030004344-A1 Thrombin or factor Xa inhibitors LAM PATRICK Y S (US) 2003-01-02 US claimed
US-6500855-B1 NITROGEN CONTAINING AROMATIC HETEROCYCLES WITH ORTHO-SUBSTITUTED P1 GROUPS; ANTICOAGULANTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-12-31 US claimed
US-20020115854-A1 Thrombin or factor Xa inhibitors LAM PATRICK Y S (US) 2002-08-22 US claimed
US-6403583-B1 ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS. BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-06-11 US claimed
US-6369227-B1 BLOOD COAGULATION BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-04-09 US claimed
EP-1140871-A1 THROMBIN OR FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP claimed
WO-2000039108-A1 THROMBIN OR FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-07-06 WO claimed
EP-1670739-A4 CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2007-08-08 EP disclosed
EP-1553947-A4 QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2006-11-29 EP disclosed
EP-1670739-A2 CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2006-06-21 EP disclosed
EP-1553947-A2 QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2005-07-20 EP disclosed
WO-2005032490-A2 CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 WO disclosed
EP-1140871-A4 THROMBIN OR FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2004-05-06 EP disclosed
US-6403583-B1 ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS. BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-06-11 US disclosed
US-6369227-B1 BLOOD COAGULATION BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-04-09 US disclosed
EP-1140941-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
EP-1140871-A1 THROMBIN OR FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
WO-2000039131-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-07-06 WO disclosed
WO-2000039108-A1 THROMBIN OR FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-07-06 WO disclosed